BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 27275102)

  • 1. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.
    Jamali R; Razavizade M; Arj A; Aarabi MH
    World J Gastroenterol; 2016 Jun; 22(21):5096-103. PubMed ID: 27275102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines.
    Jamali R; Arj A; Razavizade M; Aarabi MH
    Medicine (Baltimore); 2016 Feb; 95(5):e2630. PubMed ID: 26844476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CORRELATION BETWEEN NONALCOHOLIC FATTY LIVER DISEASE FEATURES AND LEVELS OF ADIPOKINES AND INFLAMMATORY CYTOKINES AMONG MORBIDLY OBESE INDIVIDUALS.
    Baltieri L; Chaim EA; Chaim FDM; Utrini MP; Gestic MA; Cazzo E
    Arq Gastroenterol; 2018; 55(3):247-251. PubMed ID: 30540086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipokines and cytokines in non-alcoholic fatty liver disease.
    Jarrar MH; Baranova A; Collantes R; Ranard B; Stepanova M; Bennett C; Fang Y; Elariny H; Goodman Z; Chandhoke V; Younossi ZM
    Aliment Pharmacol Ther; 2008 Mar; 27(5):412-21. PubMed ID: 18081738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.
    Fujimori N; Umemura T; Kimura T; Tanaka N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Usami Y; Sano K; Igarashi K; Matsumoto A; Tanaka E
    World J Gastroenterol; 2018 Mar; 24(11):1239-1249. PubMed ID: 29568204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity.
    Tsochatzis E; Papatheodoridis GV; Hadziyannis E; Georgiou A; Kafiri G; Tiniakos DG; Manesis EK; Archimandritis AJ
    Scand J Gastroenterol; 2008; 43(9):1128-36. PubMed ID: 18609175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis.
    Kayadibi H; Gültepe M; Yasar B; Ince AT; Ozcan O; Ipcioglu OM; Kurdas OO; Bolat B; Benek YZ; Guveli H; Atalay S; Ozkara S; Keskin O
    Dig Dis Sci; 2009 Aug; 54(8):1764-71. PubMed ID: 18989777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis.
    Cengiz M; Ozenirler S; Kocabiyik M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):57-63. PubMed ID: 26513612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease.
    Abenavoli L; Luigiano C; Guzzi PH; Milic N; Morace C; Stelitano L; Consolo P; Miraglia S; Fagoonee S; Virgilio C; Luzza F; De Lorenzo A; Pellicano R
    Panminerva Med; 2014 Jun; 56(2):189-93. PubMed ID: 24994581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity.
    Pavlides M; Banerjee R; Tunnicliffe EM; Kelly C; Collier J; Wang LM; Fleming KA; Cobbold JF; Robson MD; Neubauer S; Barnes E
    Liver Int; 2017 Jul; 37(7):1065-1073. PubMed ID: 27778429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
    Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease.
    Fitzpatrick E; Dew TK; Quaglia A; Sherwood RA; Mitry RR; Dhawan A
    Pediatr Obes; 2012 Dec; 7(6):471-9. PubMed ID: 22962039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.
    Genc H; Dogru T; Kara M; Tapan S; Ercin CN; Acikel C; Karslioglu Y; Bagci S
    Ann Hepatol; 2013; 12(4):548-55. PubMed ID: 23813132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
    Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
    Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
    Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
    Santiago-Rolón A; Purcell D; Rosado K; Toro DH
    P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.